| Identification | Back Directory | [Name]
2(3H)-Benzoxazolone, 5-[[2-[(4-fluoro-3-methoxy-5-methylphenyl)amino]-5-methyl-4-pyrimidinyl]amino]- | [CAS]
1236667-40-5 | [Synonyms]
ATI-502
ATI-50002
Ifidancitinib
Ifidancitinib(Phase2)
2(3H)-Benzoxazolone, 5-[[2-[(4-fluoro-3-methoxy-5-methylphenyl)amino]-5-methyl-4-pyrimidinyl]amino]-
5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)-one | [Molecular Formula]
C20H18FN5O3 | [MOL File]
1236667-40-5.mol | [Molecular Weight]
395.39 |
| Chemical Properties | Back Directory | [density ]
1.405±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 62.5 mg/mL (158.07 mM; Need ultrasonic) | [form ]
Solid | [pka]
8.94±0.70(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Ifidancitinib (ATI-50002) is an orally available, potent and selective inhibitor of JAK kinase 1/3 that disrupts γc cytokine signaling. Ifidancitinib is used in the research of allergy, asthma, and autoimmune diseases[1][2]. | [in vivo]
Ifidancitinib (10-50 mg/kg, oral, single dose) can induce hair regrowth and reduce associated inflammation in mice[2]. | Animal Model: | C3H/HeJ induced by AA[2] | | Dosage: | 10, 25, 50 mg/kg; single dose
0.5g/kg; daily; 12 weeks | | Administration: | Oral | | Result: | Showed that CD44+CD62L- CD8+ T effector/memory cells were significantly reduced in peripheral blood lymphoid organs of mice, the co-inhibitory receptor PD-1 was highly expressed on effector/memory CD8+ T cells, IFN-γ production was reduced, and γc cytokine regulated T cell exhaustion. Reduced inflammatory infiltrates and inflammatory markers, and the proportion of IFN-γ-producing CD8+ T cells was also significantly reduced. |
| [storage]
Store at -20°C | [References]
[1] Li, Hui; Heckrodt, Thilo J.; Chen, Yan; Mcmurtrie, Darren John; Taylor, Vanessa; Singh, Rajinder; Ding, Pingyu; Yen, Rose.Preparation of phenylaminopyrimidinylaminooxobenzooxazole derivatives for use as JAK kinase inhibitors. WO2012015972A1
[2] Zhenpeng Dai, et al. Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata. Front Immunol. 2022 Sep 20:13:955038. DOI:10.3389/fimmu.2022.955038 |
|
| Company Name: |
ChemShuttle, Inc.
|
| Tel: |
0150-83588313-811 18800520310 |
| Website: |
www.jiehuapharma.com/ |
|